Background. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion. The physiologic response to pharmacologically induced acute or chronic glycosuria has not been investigated in human diabetes.
Methods. We evaluated 66 patients with type 2 diabetes (62 ± 7 years, BMI = 31.6 ± 4.6 kg/m2, HbA1c = 55 ± 8 mmol/mol, mean ± SD) at baseline, after a single dose, and following 4-week treatment with empagliflozin (25 mg). At each time point, patients received a mixed meal coupled with dual-tracer glucose administration and indirect calorimetry.
Results. Both single-dose and chronic empagliflozin treatment caused glycosuria during fasting (median, 7.8 [interquartile range {IQR}, 4.4] g/3 hours and 9.2 [IQR, 5.2] g/3 hours) and after meal ingestion (median, 29.0 [IQR, 12.5] g/5 hours and 28.2 [IQR, 15.4] g/5 hours). After 3 hours of fasting, endogenous glucose production (EGP) was increased 25%, while glycemia was 0.9 ± 0.7 mmol/l lower (P < 0.0001 vs. baseline). After meal ingestion, glucose and insulin AUC decreased, whereas the glucagon response increased (all P < 0.001). While oral glucose appearance was unchanged, EGP was increased (median, 40 [IQR, 14] g and 37 [IQR, 11] g vs. 34 [IQR, 11] g, both P < 0.01). Tissue glucose disposal was reduced (median, 75 [IQR, 16] g and 70 [IQR, 21] g vs. 93 [IQR, 18] g, P < 0.0001), due to a decrease in both glucose oxidation and nonoxidative glucose disposal, with a concomitant rise in lipid oxidation after chronic administration (all P < 0.01). β Cell glucose sensitivity increased (median, 55 [IQR, 35] pmol•min–1•m–2•mM–1 and 55 [IQR, 39] pmol•min–1•m–2•mM–1 vs. 44 [IQR, 32] pmol•min–1•m–2•mM–1, P < 0.0001), and insulin sensitivity was improved. Resting energy expenditure rates and those after meal ingestion were unchanged.
Conclusions. In patients with type 2 diabetes, empagliflozin-induced glycosuria improved β cell function and insulin sensitivity, despite the fall in insulin secretion and tissue glucose disposal and the rise in EGP after one dose, thereby lowering fasting and postprandial glycemia. Chronic dosing shifted substrate utilization from carbohydrate to lipid.
(A) Time course of UGE during the fasting period (–180 to 0 minutes) and the period after meal ingestion (0 to 300 minutes) in patients with type 2 diabetes during the baseline study, after a single dose (acute study), and after 28 days of empagliflozin dosing (chronic study). Data were averaged over 30-minute time intervals and expressed as grams per hour. Plots represent mean ± SD. (B) The glucose excretion data in A are plotted against the corresponding mean plasma glucose concentration during the corresponding periods of urine collection (n = 66) for the baseline study (blue lines) and the 2 studies after dosing (n = 132); the latter were combined because they were fully overlapping (red lines). The blue lines are the quadratic polynomial fit and its 95% confidence intervals for the baseline data, and the red lines are the linear fit and its 95% confidence interval for the empagliflozin studies. The top x axis indicates HbA1c levels corresponding to the mean plasma glucose concentrations on the bottom x axis, derived by linear correlation of the entire data set.